Ajar Kochar1, Hussein R Al-Khalidi2, Steen M Hansen2, Jay S Shavadia2, Mayme L Roettig2, Christopher B Fordyce3, Shannon Doerfler2, Bernard J Gersh4, Timothy D Henry5, Peter B Berger6, James G Jollis2, Christopher B Granger2. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. Electronic address: ajar.kochar@duke.edu. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 3. Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada. 4. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 5. Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California. 6. New York, New York.
Abstract
OBJECTIVES: This study sought to examine whether quality improvement initiatives across multiple ST-segment elevation myocardial infarction (STEMI) systems translated to faster first medical contact (FMC)-to-device times for patients presenting with cardiogenic shock (CS). BACKGROUND: There are limited data describing contemporary rates of achieving guideline-directed FMC-to-device times for STEMI patients with CS. METHODS: From 2012 to 2014, the American Heart Association Mission: Lifeline STEMI Systems Accelerator project established a protocol-guided approach to STEMI reperfusion systems in 484 U.S. hospitals. The study was stratified by CS versus no CS at presentation and performed Cochrane-Armitage tests to evaluate trends of achieving FMC-to-device time targets. A multivariable logistic regression model assessed the association between achieving guideline-directed FMC-to-device times and mortality. RESULTS: Among 23,785 STEMI patients, 1,993 (8.4%) experienced CS at presentation. For direct presenters, patients with CS were less likely to achieve the 90-min FMC-to-device time compared with no-CS patients (37% vs. 54%; p < 0.001). For transferred patients, CS patients were even less likely to reach the 120-min FMC-to-device time compared with no-CS patients (34% vs. 47%; p < 0.0001). The Accelerator intervention did not result in improvements in the FMC-to-device times for direct-presenting CS patients (p for trend = 0.53), although there was an improvement for transferred patients (p for trend = 0.04). Direct-presenting patients arriving within 90 min had lower mortality rates compared with patients who reached after 90 min (20.49% vs. 39.12%; p < 0.001). CONCLUSIONS: Fewer than 40% of STEMI patients presenting with CS achieved guideline-directed FMC-to-device targets; delays in reperfusion for direct-presenting patients were associated with higher mortality.
OBJECTIVES: This study sought to examine whether quality improvement initiatives across multiple ST-segment elevation myocardial infarction (STEMI) systems translated to faster first medical contact (FMC)-to-device times for patients presenting with cardiogenic shock (CS). BACKGROUND: There are limited data describing contemporary rates of achieving guideline-directed FMC-to-device times for STEMI patients with CS. METHODS: From 2012 to 2014, the American Heart Association Mission: Lifeline STEMI Systems Accelerator project established a protocol-guided approach to STEMI reperfusion systems in 484 U.S. hospitals. The study was stratified by CS versus no CS at presentation and performed Cochrane-Armitage tests to evaluate trends of achieving FMC-to-device time targets. A multivariable logistic regression model assessed the association between achieving guideline-directed FMC-to-device times and mortality. RESULTS: Among 23,785 STEMI patients, 1,993 (8.4%) experienced CS at presentation. For direct presenters, patients with CS were less likely to achieve the 90-min FMC-to-device time compared with no-CS patients (37% vs. 54%; p < 0.001). For transferred patients, CS patients were even less likely to reach the 120-min FMC-to-device time compared with no-CS patients (34% vs. 47%; p < 0.0001). The Accelerator intervention did not result in improvements in the FMC-to-device times for direct-presenting CS patients (p for trend = 0.53), although there was an improvement for transferred patients (p for trend = 0.04). Direct-presenting patients arriving within 90 min had lower mortality rates compared with patients who reached after 90 min (20.49% vs. 39.12%; p < 0.001). CONCLUSIONS: Fewer than 40% of STEMI patients presenting with CS achieved guideline-directed FMC-to-device targets; delays in reperfusion for direct-presenting patients were associated with higher mortality.
Authors: Alastair G Proudfoot; Antonis Kalakoutas; Susanna Meade; Mark J D Griffiths; Mir Basir; Francesco Burzotta; Sharon Chih; Eddy Fan; Jonathan Haft; Nasrien Ibrahim; Natalie Kruit; Hoong Sern Lim; David A Morrow; Jun Nakata; Susanna Price; Carolyn Rosner; Robert Roswell; Mark A Samaan; Marc D Samsky; Holger Thiele; Alexander G Truesdell; Sean van Diepen; Michelle Doughty Voeltz; Peter M Irving Journal: Circ Heart Fail Date: 2021-11-22 Impact factor: 8.790
Authors: Behnam N Tehrani; Alexander G Truesdell; Mitchell A Psotka; Carolyn Rosner; Ramesh Singh; Shashank S Sinha; Abdulla A Damluji; Wayne B Batchelor Journal: JACC Heart Fail Date: 2020-11 Impact factor: 12.035
Authors: Saraschandra Vallabhajosyula; Saarwaani Vallabhajosyula; Shannon M Dunlay; Sharonne N Hayes; Patricia J M Best; Jorge A Brenes-Salazar; Amir Lerman; Bernard J Gersh; Allan S Jaffe; Malcolm R Bell; David R Holmes; Gregory W Barsness Journal: Mayo Clin Proc Date: 2020-09 Impact factor: 7.616
Authors: Ahmad Alrawashdeh; Ziad Nehme; Brett Williams; Karen Smith; Angela Brennan; Diem T Dinh; Danny Liew; Jeffrey Lefkovits; Dion Stub Journal: Open Heart Date: 2021-05
Authors: Gábor Tamás Szabó; András Ágoston; Gábor Csató; Ildikó Rácz; Tamás Bárány; Gábor Uzonyi; Miklós Szokol; Balázs Sármán; Éva Jebelovszki; István Ferenc Édes; Dániel Czuriga; Rudolf Kolozsvári; Zoltán Csanádi; István Édes; Zsolt Kőszegi Journal: Sensors (Basel) Date: 2021-02-01 Impact factor: 3.576
Authors: Corinna N Lang; Klaus Kaier; Viviane Zotzmann; Peter Stachon; Torben Pottgiesser; Constantin von Zur Muehlen; Manfred Zehender; Daniel Duerschmied; Bonaventura Schmid; Christoph Bode; Tobias Wengenmayer; Dawid L Staudacher Journal: Clin Res Cardiol Date: 2020-11-30 Impact factor: 5.460